Skip to main content

Table 1 Screening means and baseline means (post flare) for pain, swollen and tender joint counts and HAQ scores by treatment groups and by concomitant therapy subgroups

From: Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib

 

Placebo

Etoricoxib 10/30/60 mg

Etoricoxib 90 mg

Screening/Baseline

Screening/Baseline

Screening/Baseline

Pain VAS

   

Neither

42.8/73.4

39.8/69.0*

37.22/70.6

bDMARD

40.2/71.2

39.7/69.4

36.17/67.8

CS

38.9/73.1

42.2/74.9

38.23/72.6

Both

40.1/69.9

42.7/71.5

48.50 / 73.8

66-SJC

   

Neither

8.1/16.2

7.3/16.6

7.41/15.8

bDMARD

9.8/16.9

10.1/15.3

10.17/19.1

CS

7.9/15.5

8.9/19.8

7.19 / 14.5

Both

10.2/16.6

11.9/17.2

9.63/18.9

68-TJC

   

Neither

13.7/26.5

13.0/26.4

13.86/25.8

bDMARD

12.1/29.6

16.8/31.9

15.86/28.9

CS

12.5/26.2

12.8/26.8

14.25/25.4

Both

13.8/29.1

14.2/29.6

12.81/28.8

HAQ-score

   

Neither

0.99/1.32

0.89/1.18

0.89/1.14

bDMARD

0.86/1.32

1.12/1.45

1.01/1.35

CS

1.00/1.28

1.02/1.42

0.97/1.26

Both

1.57/1.67

1.10/1.43**

1.45/1.64

  1. bDMARDs = Biological disease-modifying antirheumatic drugs;CS = Corticosteroids;VAS = Visual analogue scale.
  2. 66-SJC = Swollen joint count of 66 joints; 68-TJC = Tender joint count of 68 joints; HAQ = Health assessment questionnaire.
  3. *p = 0.050 for difference between baseline values for placebo and etoricoxib 10/30/60; **p = 0.036 for difference between screening values for placebo and etoricoxib (Other than these two instances out of the 96 treatment comparisons that were conducted, there were no consistently observed statistical differences in screening/baseline values).